Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Candel Therapeutics reported Q2 2026 financial results showing increased R&D and administrative expenses due to advanced clinical activities. The company announced plans to submit a Biologics License Application (BLA) for aglatimagene in localized prostate cancer in Q4 2026, supported by published positive phase 3 data and recent clinical trial pro…